Consider telehealth company LifeMD (LFMD) as a value opportunity, as the stock has dropped significantly despite strong fundamentals and appears undervalued compared to its competitor, Hims (HIMS). LFMD is uniquely positioned by working with insurance to provide branded GLP-1 drugs like Wegovy and Ozempic, is cash-flow positive,

LifeMD (LFMD)

• Q3 Performance: The company reported a "good" Q3 2023. Despite this, the stock dropped 17% since the report. The host believes this drop is due to negative market sentiment towards small-cap stocks and macro liquidity issues, not the company's performance.
• Business Model: LifeMD is a telehealth company with an end-to-end platform that includes an app, an electronic medical records system, and employed doctors.
  • It operates on a subscription model, offering doctor access for $19 a month.
  • It has its own pharmacy and is converting it to a 503B facility, which is expected to improve profit margins.
• Financial Health:
  • The company is cash flow positive with no debt.
  • It has a high gross margin of 85%, which is noted as being almost 10% higher than its competitor, Hims.
• GLP-1 Business: This is a significant part of the company, making up roughly 50% of its business.
  • A key differentiator is that LifeMD works with insurance companies to get branded GLP-1 drugs like Wegovy and Ozempic covered for patients.
  • The host states LifeMD is the "last player standing" among its peers with partnerships with Novo Nordisk and Eli Lilly for these branded drugs.
• Valuation: The host views LFMD as significantly undervalued compared to its peer, Hims.
  • It is described as being "three times cheaper than HIMS" on a price-to-growth basis.
  • Its Enterprise Value to Forward Revenue is only 0.5x, while its Enterprise Value to EBITDA is 7.
  • Analysts are forecasting 24% top-line revenue growth over the next 12 months.
• Risks Mentioned:
  • As a small-cap stock, it is less understood by the market and more prone to sell-offs.
  • It faces headwinds from patients switching to cheaper, compounded GLP-1s advertised on social media.

Takeaways

• Value Play: The host presents LFMD as a potential value play in the telehealth sector, appearing cheap relative to its growth, profitability, and its main competitor, HIMS.
• Higher Risk/Reward: While it may offer more value, it is also a riskier investment due to its smaller size and market perception. The stock has been a "roller coaster."
• Key Catalysts to Watch:
  • Medicare Coverage (2026): A potential decision by Medicare to cover GLP-1 drugs in 2026 could be an "enormous catalyst."
  • Oral GLP-1s (2026): The potential arrival of oral versions of drugs like Wegovy in 2026 could drive significant sales, as it would appeal to patients who dislike injections. LifeMD could be one of the first platforms to offer them.
• Competitive Advantage: LifeMD's strategy of working with insurance to provide branded GLP-1s is a major distinction from competitors and could be a long-term advantage, especially if regulators crack down on compounded alternatives.

Hims & Hers Health, Inc. (HIMS)

• Q3 Performance: The company reported an "outstanding" Q3 2023, beating revenue expectations by a significant margin.
• Stock Performance: Despite the strong quarter, the stock dropped 18.72% since the report, a larger drop than LifeMD experienced. The host attributes this to the same negative macro factors affecting the small-cap market.
• Business Model: Unlike LifeMD, HIMS does not accept insurance at all. It has a small business in compounded GLP-1s but primarily focuses on generic drugs. The company previously had a deal for branded Ozempic but has since ended it.
• Valuation: The host considers HIMS to be much more expensive than LifeMD, though still "way too cheap" on an absolute basis.
  • Its Enterprise Value to Forward Revenue is 2x (compared to 0.5x for LFMD).
  • Its gross margin is noted as being nearly 10% lower than LifeMD's.

Takeaways

• Stronger Performer, Higher Price: HIMS demonstrated stronger quarterly performance but trades at a significantly higher valuation than LFMD.
• Different Strategy: Investors should note the strategic difference in its business model, which avoids insurance entirely. This makes it a pure cash-pay business, which has different risks and benefits compared to LifeMD's insurance-integrated model.
• Market Volatility: Despite being a larger company, its stock is described as a "roller coaster," indicating high volatility that is not always tied to company performance.

Investment Theme: GLP-1 Weight-Loss Drugs

• Market Driver: The discussion highlights the GLP-1 market as a massive growth driver for telehealth companies like LifeMD and Hims.
• Branded vs. Compounded: A key conflict in the market is between expensive, FDA-approved branded GLP-1s (like Wegovy and Ozempic) and cheap, often unregulated compounded versions.
  • LifeMD is positioned on the branded side, leveraging insurance to make them more affordable.
  • The availability of cheap compounded drugs is a direct headwind to companies selling branded versions.
• Future Catalysts: The entire sector could see a massive expansion based on two potential events in 2026:
  • Medicare Coverage: If Medicare begins covering GLP-1s for weight loss, it would open up a vast new patient population.
  • Oral Formulations: The approval of oral GLP-1 pills would remove the barrier of injections, likely attracting a new wave of customers and driving sales for platforms that offer them.

Takeaways

• Long-Term Growth Theme: The GLP-1 market represents a significant, long-term growth opportunity. Investors can gain exposure through telehealth platforms that are integrating these drugs into their services.
• Monitor Key Events: Keep a close watch on news related to Medicare coverage decisions and the FDA approval timeline for oral GLP-1s, as these are presented as major, market-moving catalysts for 2026.
• Understand Company Positioning: When evaluating companies in this space, it's crucial to understand if their strategy relies on branded drugs (like LFMD) or compounded/generic alternatives (like HIMS), as each approach has different risks and growth pathways.